Tilray Medical announced Tuesday that Portuguese regulators have approved its quality control laboratory in Cantanhede, Portugal, to conduct microbiological and chemical and physical testing in-house, a move the company says will reduce costs and accelerate the release of medical marijuana products for international markets.
The authorization was granted by INFARMED, Portugal’s National Authority of Medicines and Health Products, and applies to Tilray’s European Union Good Manufacturing Practice (EU-GMP) certified production facility. The approval allows the company to perform critical quality testing directly at the facility rather than relying on outside laboratories.
According to Tilray, bringing these testing capabilities in-house will shorten the time required to move marijuana products from harvest through quality verification and into commercial distribution. The company also expects the change to reduce batch-release expenses and provide greater control over its international supply chain.
The Cantanhede facility serves as a major production and distribution center for Tilray’s medical marijuana operations in Europe, supplying regulated markets that include Germany, the United Kingdom, Poland and Italy.
Rajnish Ohri, president of international operations at Tilray Brands, said the approval strengthens the company’s ability to meet pharmaceutical quality standards while improving operational efficiency.
“This approval further strengthens our platform in Portugal by bringing advanced quality testing closer to cultivation and production,” said Ohri. “It gives us greater speed, control, and flexibility across our international supply chain.”
The regulatory authorization follows increased production at Tilray’s Portugal facility and the company’s expansion of Tilray Medical-branded marijuana medicines in the United Kingdom through Lyphe Clinic and Lyphe Dispensary.
Tilray, which trades on the Nasdaq and Toronto Stock Exchange under the ticker TLRY, operates medical marijuana businesses across multiple international markets. The company says its medical division has supplied patients in more than 20 countries across five continents.
Tilray did not provide specific estimates for how much the new testing authorization will reduce costs or shorten product-release timelines.
